IrniCann

IrniCann
Product Description

Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​• An estimated 250,000 new cases of GBM per year worldwide.​1• The preclinical studies demonstrated that IrniCan® was cytotoxic to Glioblastoma tumor and stem cells, reducing cell viability and inducing), which could establish a new benchmarkcaspase-dependent cell apoptosis (or cell death in treating GBM by improving safety and efficacy profiles.2

Read more Show less

Argent BioPharma ltd

  • GB
  • 2024
    On CPHI since
  • 1
    Certificates
  • 50 - 99
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

Argent BioPharma ltd

  • GB
  • 2024
    On CPHI since
  • 1
    Certificates
  • 50 - 99
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile

More Products from Argent BioPharma ltd (4)

  • CannEpil

    Product CannEpil

    CannEpil®, one of Argent BioPharma's flagship products, is an enhanced iteration of a compounded isolated cannabinoid formulation. It leverages well-known historical data to become one of the first compounded prescription investigational drugs used for seizure management over the past years. The active ing...
  • CimetrA

    Product CimetrA

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date.
    Results of Preclinical and Clinical program, meeting FDA guide...
  • CogniCann

    Product CogniCann

    CogniCann® is an Investigational Medicinal Product based on two APIs, low CBD and high THC, designed to be used for symptoms associated with Dementia and Alzheimer's.

    A Phase II, randomized, double-blind cross-over, placebo-controlled clinical study designed to evaluate the clinical efficacy of ...
  • DerNaPol

    Product DerNaPol

    Chronic wounds are a major global health issue, costing billions in treatment annually (e.g., £3.2 billion in the UK 1in 2015; $28.1 to $96.8 billion in the USA in 20142). These wounds cause extreme sufferingwith severe symptoms, often complicated by antibiotic-resistant infections,impenetrablebiofilmsand ...

Argent BioPharma ltd resources (1)

  • Argent BioPharma video presentation

    Video Argent BioPharma video presentation

    Introducing Argent BioPharma's Vision for the future.We're excited to share our journey in transforming healthcare through innovation. Our focus on addressing CNS conditions and immunology is driven by our commitment to advancing treatments for unmet medical needs.


    watch the video to learn more about our vision and innovative approach!
    2024-09-10